Responses to Nutritional Chromium Supplements for Type 2 Diabetes Mellitus

Preview this chapter:

Responses to Nutritional Chromium Supplements for Type 2 Diabetes Mellitus, Page 1 of 1

< Previous page | Next page > /docserver/preview/fulltext/9789815040227/chap2-1.gif

Based on research, several scientific publications proposed dietary trivalent chromium as an attractive alternative for the prevention of hyperglycemia in people at high risk of type 2 diabetes mellitus (T2DM). The objective of the study is to determine the influence of chromium on the reaction of glucose and insulin in individuals with type 2 diabetes and healthy subjects. The study was based on several clinical reports of randomized clinical trials (RCTs). Available RCTs that were issued before December 2020 were routinely looked for in PubMed/Medline, Scopus, Web of Sciences, Google Scholar, and Cochrane Library. Keywords, such as “chromium” OR “chromium supplements” OR “chromium picolinate” in combination with “type 2 diabetes” were also checked in English. The results of these clinical studies support the view that chromium can improve both insulin and glucose metabolism in patients with T2DM, especially in the form of dietary supplements (chromium picolinate). However, insufficient data are available to create a conclusive hypothesis that nutritional supplements of chromium could be useful for the treatment of T2DM, and thus there is no need to endorse a general prescription for the management of diabetes using these supplements. Chromium supplements have minimal usefulness based on the lower impact of established evidence, and there is no reason for promoting their use for glycemic control in patients with existing T2DM. Well-designed, high-quality, broad, and long-term trials are required to improve the current data and ensure the protection and efficacy of drugs.